Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Immune cell profiling in cancer: molecular approaches to cell-specific identification.

Lyons YA, Wu SY, Overwijk WW, Baggerly KA, Sood AK.

NPJ Precis Oncol. 2017 Aug 15;1(1):26. doi: 10.1038/s41698-017-0031-0. eCollection 2017. Review.

2.

Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response.

Khong H, Volmari A, Sharma M, Dai Z, Imo CS, Hailemichael Y, Singh M, Moore DT, Xiao Z, Huang XF, Horvath TD, Hawke DH, Overwijk WW.

J Immunol. 2018 May 15;200(10):3464-3474. doi: 10.4049/jimmunol.1700467. Epub 2018 Apr 11.

PMID:
29643190
3.

Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.

Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW.

J Clin Invest. 2018 Apr 2;128(4):1338-1354. doi: 10.1172/JCI93303. Epub 2018 Feb 26.

4.

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.

Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK.

Oncotarget. 2017 Aug 24;8(57):96496-96505. doi: 10.18632/oncotarget.20410. eCollection 2017 Nov 14.

5.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

6.

Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.

Singh M, Vianden C, Cantwell MJ, Dai Z, Xiao Z, Sharma M, Khong H, Jaiswal AR, Faak F, Hailemichael Y, Janssen LME, Bharadwaj U, Curran MA, Diab A, Bassett RL, Tweardy DJ, Hwu P, Overwijk WW.

Nat Commun. 2017 Nov 13;8(1):1447. doi: 10.1038/s41467-017-01572-7.

7.

The immune system in cancer metastasis: friend or foe?

Janssen LME, Ramsay EE, Logsdon CD, Overwijk WW.

J Immunother Cancer. 2017 Oct 17;5(1):79. doi: 10.1186/s40425-017-0283-9. Review.

8.

Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.

Overwijk WW.

Curr Opin Immunol. 2017 Aug;47:103-109. doi: 10.1016/j.coi.2017.07.015. Epub 2017 Aug 12. Review.

PMID:
28806603
9.

Absence of Grail promotes CD8+ T cell anti-tumour activity.

Haymaker C, Yang Y, Wang J, Zou Q, Sahoo A, Alekseev A, Singh D, Ritthipichai K, Hailemichael Y, Hoang ON, Qin H, Schluns KS, Wang T, Overwijk WW, Sun SC, Bernatchez C, Kwak LW, Neelapu SS, Nurieva R.

Nat Commun. 2017 Aug 10;8(1):239. doi: 10.1038/s41467-017-00252-w.

10.

Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter.

Ritthipichai K, Haymaker CL, Martinez M, Aschenbrenner A, Yi X, Zhang M, Kale C, Vence LM, Roszik J, Hailemichael Y, Overwijk WW, Varadarajan N, Nurieva R, Radvanyi LG, Hwu P, Bernatchez C.

Clin Cancer Res. 2017 Oct 15;23(20):6151-6164. doi: 10.1158/1078-0432.CCR-16-1217. Epub 2017 Jul 28.

PMID:
28754817
11.

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.

Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, Xiong W, Zang W, Guo L, Liu Y, Dong ZJ, Overwijk WW, Hwu P, Yi Q, Kwak L, Yang Z, Mak TW, Li W, Radvanyi LG, Ni L, Liu D, Dong C.

Cell Res. 2017 Aug;27(8):1034-1045. doi: 10.1038/cr.2017.90. Epub 2017 Jul 7.

12.

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB.

Neuro Oncol. 2017 Aug 1;19(8):1047-1057. doi: 10.1093/neuonc/nox026.

13.

Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor.

Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW.

Neoplasia. 2017 Mar;19(3):237-249. doi: 10.1016/j.neo.2016.07.009.

14.

The making of a killer (T cell).

Overwijk WW.

Oncotarget. 2017 Feb 14;8(7):10767-10768. doi: 10.18632/oncotarget.15229. No abstract available.

15.

Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy.

Tzeng A, Kauke MJ, Zhu EF, Moynihan KD, Opel CF, Yang NJ, Mehta N, Kelly RL, Szeto GL, Overwijk WW, Irvine DJ, Wittrup KD.

Cell Rep. 2016 Dec 6;17(10):2503-2511. doi: 10.1016/j.celrep.2016.11.020.

16.

Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.

Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW.

Cancer Res. 2017 Feb 15;77(4):839-850. doi: 10.1158/0008-5472.CAN-15-3142. Epub 2016 Nov 7.

17.

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.

Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola F, Hwu P, Grimm E, Radvanyi L.

Cancer Immunol Res. 2016 Nov;4(11):983-994. Epub 2016 Oct 3.

18.

The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.

Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S.

Int Rev Immunol. 2016 Jul 3;35(4):325-339. Epub 2014 Sep 26. Review.

19.
20.

Adjuvants for peptide-based cancer vaccines.

Khong H, Overwijk WW.

J Immunother Cancer. 2016 Sep 20;4:56. doi: 10.1186/s40425-016-0160-y. eCollection 2016. Review.

21.

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.

Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Galon J, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM.

J Immunother Cancer. 2016 Jun 21;4:37. doi: 10.1186/s40425-016-0142-0. eCollection 2016.

22.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.

Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.

23.

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P.

Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8.

24.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

25.

Intratumoral immunotherapy for melanoma.

Singh M, Overwijk WW.

Cancer Immunol Immunother. 2015 Jul;64(7):911-21. doi: 10.1007/s00262-015-1727-z. Epub 2015 Jun 7. Review.

PMID:
26050024
26.

Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways.

Anthony SM, Howard ME, Hailemichael Y, Overwijk WW, Schluns KS.

PLoS One. 2015 Mar 10;10(3):e0120274. doi: 10.1371/journal.pone.0120274. eCollection 2015.

27.

Human CD4(+) T cells spontaneously detect somatic mutations in cancer cells.

Overwijk WW.

Nat Med. 2015 Jan;21(1):12-4. doi: 10.1038/nm.3783. No abstract available.

28.

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW.

J Immunol. 2014 Nov 1;193(9):4722-31. doi: 10.4049/jimmunol.1401160. Epub 2014 Sep 24.

29.

Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors.

Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V.

Transl Oncol. 2014 Aug;7(4):484-92. doi: 10.1016/j.tranon.2014.05.008. Epub 2014 Jun 23.

30.

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice.

Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW.

Nat Med. 2014 Jun;20(6):676-81. doi: 10.1038/nm.3560. Epub 2014 May 25.

31.

Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.

Hailemichael Y, Overwijk WW.

Int J Biochem Cell Biol. 2014 Aug;53:46-50. doi: 10.1016/j.biocel.2014.04.019. Epub 2014 May 2. Review.

32.

2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK.

Nat Commun. 2014 Mar 12;5:3459. doi: 10.1038/ncomms4459.

33.

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard.

Hailemichael Y, Overwijk WW.

Oncoimmunology. 2013 Jul 1;2(7):e24743. Epub 2013 Apr 30.

34.

Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.

Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P.

J Immunother. 2013 May;36(4):276-86. doi: 10.1097/CJI.0b013e31829419f3.

35.

Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.

Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Sowell RT, Schluns KS, Davis RE, Hwu P, Overwijk WW.

Nat Med. 2013 Apr;19(4):465-72. doi: 10.1038/nm.3105. Epub 2013 Mar 3.

36.

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA.

Clin Cancer Res. 2013 Mar 1;19(5):1225-31. doi: 10.1158/1078-0432.CCR-12-1630. Epub 2013 Jan 10.

37.

Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors.

Overwijk WW, Wang E, Marincola FM, Rammensee HG, Restifo NP.

J Immunother Cancer. 2013 Jul 29;1:11. doi: 10.1186/2051-1426-1-11. eCollection 2013. Review.

38.

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P.

Clin Cancer Res. 2013 Jan 15;19(2):393-403. doi: 10.1158/1078-0432.CCR-12-1626. Epub 2012 Nov 30.

39.

Differential expression of the G-protein-coupled formyl Peptide receptor in melanoma associates with aggressive phenotype.

Chakravarti N, Peddareddigari VG, Warneke CL, Johnson MM, Overwijk WW, Hwu P, Prieto VG.

Am J Dermatopathol. 2013 Apr;35(2):184-90. doi: 10.1097/DAD.0b013e31825b2506.

PMID:
23147350
40.

Harnessing the power of the immune system to target cancer.

Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P.

Annu Rev Med. 2013;64:71-90. doi: 10.1146/annurev-med-112311-083918. Epub 2012 Oct 22. Review.

PMID:
23092383
41.

Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P.

Blood. 2012 Nov 29;120(23):4533-43. doi: 10.1182/blood-2012-02-407163. Epub 2012 Aug 30.

42.

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.

Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P.

Cancer Res. 2012 Oct 15;72(20):5209-18. doi: 10.1158/0008-5472.CAN-12-1187. Epub 2012 Aug 20.

43.

Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release.

Jayaraman P, Parikh F, Lopez-Rivera E, Hailemichael Y, Clark A, Ma G, Cannan D, Ramacher M, Kato M, Overwijk WW, Chen SH, Umansky VY, Sikora AG.

J Immunol. 2012 Jun 1;188(11):5365-76. doi: 10.4049/jimmunol.1103553. Epub 2012 Apr 23.

44.

Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.

Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizée G, Zhou D, Overwijk WW, Hwu P.

J Immunother. 2012 Apr;35(3):276-82. doi: 10.1097/CJI.0b013e31824e7f43.

45.

Conference scene: immune effector mechanisms in tumor immunity.

Sikora AG, Hailemichael Y, Overwijk WW.

Immunotherapy. 2012 Feb;4(2):141-3. doi: 10.2217/imt.11.177.

46.

Cell-intrinsic role for IFN-α-STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response.

Li HS, Gelbard A, Martinez GJ, Esashi E, Zhang H, Nguyen-Jackson H, Liu YJ, Overwijk WW, Watowich SS.

Blood. 2011 Oct 6;118(14):3879-89. doi: 10.1182/blood-2011-04-349761. Epub 2011 Aug 9.

47.

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.

Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG.

Clin Cancer Res. 2011 Jul 15;17(14):4882-91. doi: 10.1158/1078-0432.CCR-10-2769. Epub 2011 Jun 1.

48.

Antitumor activity mediated by CpG: the route of administration is critical.

Lou Y, Liu C, Lizée G, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D, Overwijk WW, Hwu P.

J Immunother. 2011 Apr;34(3):279-88. doi: 10.1097/CJI.0b013e31820d2a05.

PMID:
21389870
49.

Induction of TLR4-dependent CD8+ T cell immunity by murine β-defensin2 fusion protein vaccines.

Park HJ, Qin H, Cha SC, Sharma R, Chung Y, Schluns KS, Neelapu SS, Overwijk WW, Hwu P, Kwak LW.

Vaccine. 2011 Apr 18;29(18):3476-82. doi: 10.1016/j.vaccine.2011.02.061. Epub 2011 Mar 5.

PMID:
21382485
50.

Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses.

Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizée G, Hwu P.

Clin Cancer Res. 2010 Nov 15;16(22):5458-68. doi: 10.1158/1078-0432.CCR-10-0712. Epub 2010 Oct 1.

Supplemental Content

Loading ...
Support Center